Griekenland -
Grieks -
Εθνικός Οργανισμός Φαρμάκων
capd/fresenius capd11 4.25% σε γλυκ sol.per.di
medispes Α.Ε.Β.Ε - ΔΙΑΛΥΜΑ ΠΕΡΙΤΟΝΑΙΚΗΣ ΔΙΑΠΙΔΥΣΗΣ (ΚΑΘΑΡΣΗΣ) - capd11 4.25% σε γλυκ
Griekenland -
Grieks -
Εθνικός Οργανισμός Φαρμάκων
capd/fresenius capd12 2.30% σε γλυκ sol.per.di
medispes Α.Ε.Β.Ε - ΔΙΑΛΥΜΑ ΠΕΡΙΤΟΝΑΙΚΗΣ ΔΙΑΠΙΔΥΣΗΣ (ΚΑΘΑΡΣΗΣ) - capd12 2.30% σε γλυκ
Cyprus -
Grieks -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
lipitor 40mg film coated tablets
viatris hellas ltd (0000012378) 253-255 mesoghion avenue, n. psychiko, athens, 15451 - atorvastatin calcium - film coated tablets - 40mg - atorvastatin calcium (8000001537) 43,4mg - atorvastatin
Cyprus -
Grieks -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
lipitor 20mg film coated tablets
viatris hellas ltd (0000012378) 253-255 mesoghion avenue, n. psychiko, athens, 15451 - atorvastatin calcium - film coated tablets - 20mg - atorvastatin calcium (8000001537) 21,7mg - atorvastatin
Cyprus -
Grieks -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
lipitor 10mg film coated tablets
viatris hellas ltd (0000012378) 253-255 mesoghion avenue, n. psychiko, athens, 15451 - atorvastatin calcium - film coated tablets - 10mg - atorvastatin calcium (8000001537) 10,85mg - atorvastatin
Cyprus -
Grieks -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
zarator 20mg film coated tablets
viatris hellas ltd (0000012378) 253-255 mesoghion avenue, n. psychiko, athens, 15451 - atorvastatin calcium - film coated tablets - 20mg - atorvastatin calcium (8000001537) 21,7mg
Cyprus -
Grieks -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
zarator 40mg film coated tablets
viatris hellas ltd (0000012378) 253-255 mesoghion avenue, n. psychiko, athens, 15451 - atorvastatin calcium - film coated tablets - 40mg - atorvastatin calcium (8000001537) 43,4mg
Cyprus -
Grieks -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
zarator 10mg film coated tablets
viatris hellas ltd (0000012378) 253-255 mesoghion avenue, n. psychiko, athens, 15451 - atorvastatin calcium - film coated tablets - 10mg - atorvastatin calcium (8000001537) 10,85mg
Europese Unie -
Grieks -
EMA (European Medicines Agency)
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - Καρκίνωμα, σκουός κύτταρο - Αντινεοπλασματικοί παράγοντες - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
